SELLAS Life Sciences Group, Inc.
Complete the U.S. phase 1 trial for GFH009
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 6 Apr 2022
- Due
- 31 Dec 2022
- Delivered
- by 11 May 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we are planning to complete the U.S. trial by year end”
What we found
Evidence strength A What the grades mean
The company announced the completion of the safety evaluation stage of the Phase 1 trial in April 2023, which occurred after the 2022 year-end deadline.
-
A SELLAS Life Sciences Group, Inc. 10-Q filed 2023-05-11
“In April 2023, we announced the completion of the safety evaluation stage of the highest dose cohort of patients with AML who relapsed after or were refractory to available antileukemic therapies in our Phase 1 dose escalation clinical trial of GFH009.” ✓ confirmed on the page
Market reaction: the shares moved -5.8% against the S&P 500 over the three sessions around the disclosure (10 May 2023 to 15 May 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +181 days
- 2 versions
-
Version 1 · original · stated 6 Apr 2022
Deadline 31 Dec 2022 (“by year end”)
-
Version 2 · stated 11 Aug 2022
Deadline 31 Mar 2023 (“early in 2023”) · wording firm
“Enrollment for the study is scheduled to be completed in early in 2023”
-
Version 3 · stated 11 May 2023
Deadline 30 Jun 2023 (“during the second quarter of 2023”) · wording expected
“SELLAS plans to commence a Phase 2a trial with GFH009... during the second quarter of 2023”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- U.S. phase 1 trial for GFH009
- Where
- U.S.
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-SLS-001987 · Corrections policy